Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Alpha-tectorin is a large extracellular matrix glycoprotein encoded by the TECTA gene, predominantly found in the tectorial membrane of the cochlea in the inner ear[3][5]. It is critical for normal hearing by contributing to the mechanical properties of the tectorial membrane, enabling the proper transmission of sound-induced vibrations to sensory hair cells, which is essential for auditory signal transduction[1][3][4][5]. Alpha-tectorin is a GPI-anchored protein with multiple protein–protein interaction domains that organize the structure and assembly of the tectorial membrane[1]. Mutations in the TECTA gene cause both autosomal dominant (DFNA8/12) and autosomal recessive (DFNB21) forms of nonsyndromic sensorineural hearing loss, due to defective structure or loss of function of the tectorial membrane[2][3][4]. It is not currently considered a conventional therapeutic target (e.g. receptor or enzyme), and there are no known drugs that directly interact with alpha-tectorin[2][3][5]. However, TECTA gene testing can serve as a biomarker to diagnose genetic forms of hearing loss and guide family counseling for hereditary deafness[2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Alpha-tectorin (TECTA).